10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss their phenotype and acquire mesenchymal traits, including increased migratory and invasive capacities. EMT is involved in physiological processes, such as embryogenesis and wound healing, and in pathological processes such as cancer, playing a pivotal role in tumor progression and metastasis. Pituitary tumors, although typically benign, can be locally invasive. Different studies have shown the association of EMT with increased tumor size and invasion in pituitary tumors, and in particular with a poor response to Somatostatin Receptor Ligands (SRLs) treatment in GH-producing pituitary tumors, the main cause of acromegaly. This review will summarize the current knowledge regarding EMT and SRLs resistance in acromegaly and, based on this relation, will suggest new biomarkers and possible therapies to SRLs resistant tumors.

          Related collections

          Most cited references90

          • Record: found
          • Abstract: found
          • Article: not found

          EMT: 2016.

          The significant parallels between cell plasticity during embryonic development and carcinoma progression have helped us understand the importance of the epithelial-mesenchymal transition (EMT) in human disease. Our expanding knowledge of EMT has led to a clarification of the EMT program as a set of multiple and dynamic transitional states between the epithelial and mesenchymal phenotypes, as opposed to a process involving a single binary decision. EMT and its intermediate states have recently been identified as crucial drivers of organ fibrosis and tumor progression, although there is some need for caution when interpreting its contribution to metastatic colonization. Here, we discuss the current state-of-the-art and latest findings regarding the concept of cellular plasticity and heterogeneity in EMT. We raise some of the questions pending and identify the challenges faced in this fast-moving field.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            EMT Transition States during Tumor Progression and Metastasis

            Epithelial-mesenchymal transition (EMT) is a process in which epithelial cells acquire mesenchymal features. In cancer, EMT is associated with tumor initiation, invasion, metastasis, and resistance to therapy. Recently, it has been demonstrated that EMT is not a binary process, but occurs through distinct cellular states. Here, we review the recent studies that demonstrate the existence of these different EMT states in cancer and the mechanisms regulating their functions. We discuss the different functional characteristics, such as proliferation, propagation, plasticity, invasion, and metastasis associated with the distinct EMT states. We summarize the role of the transcriptional and epigenetic landscapes, gene regulatory network and their surrounding niche in controlling the transition through the different EMT states.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Guidelines and definitions for research on epithelial–mesenchymal transition

              Epithelial–mesenchymal transition (EMT) encompasses dynamic changes in cellular organization from epithelial to mesenchymal phenotypes, which leads to functional changes in cell migration and invasion. EMT occurs in a diverse range of physiological and pathological conditions and is driven by a conserved set of inducing signals, transcriptional regulators and downstream effectors. With over 5,700 publications indexed by Web of Science in 2019 alone, research on EMT is expanding rapidly. This growing interest warrants the need for a consensus among researchers when referring to and undertaking research on EMT. This Consensus Statement, mediated by ‘the EMT International Association’ (TEMTIA), is the outcome of a 2-year-long discussion among EMT researchers and aims to both clarify the nomenclature and provide definitions and guidelines for EMT research in future publications. We trust that these guidelines will help to reduce misunderstanding and misinterpretation of research data generated in various experimental models and to promote cross-disciplinary collaboration to identify and address key open questions in this research field. While recognizing the importance of maintaining diversity in experimental approaches and conceptual frameworks, we emphasize that lasting contributions of EMT research to increasing our understanding of developmental processes and combatting cancer and other diseases depend on the adoption of a unified terminology to describe EMT.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                15 March 2021
                2021
                : 12
                : 646210
                Affiliations
                [1] 1 Endocrine Tumours Lab, Program of Predictive and Personalized Medicine of Cancer (PMPPC), Germans Trias i Pujol Research Institute (IGTP) , Badalona, Spain
                [2] 2 Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital , Badalona, Spain
                [3] 3 Department of Medicine, Autonomous University of Barcelona , Bellaterra, Spain
                Author notes

                Edited by: Manuel D. Gahete, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain

                Reviewed by: Marta Korbonits, Queen Mary University of London, United Kingdom; Sabrina Chiloiro, Catholic University of the Sacred Heart, Italy

                *Correspondence: Manel Puig-Domingo, mpuigd@ 123456igtp.cat ; Mireia Jordà, mjorda@ 123456igtp.cat

                †These authors have contributed equally to this work and share senior authorship

                This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology

                Article
                10.3389/fendo.2021.646210
                8006574
                33790868
                2b435616-12b5-4c11-9762-2491cfd28d00
                Copyright © 2021 Gil, Jordà, Soldevila and Puig-Domingo

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 25 December 2020
                : 22 February 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 90, Pages: 7, Words: 3476
                Funding
                Funded by: Instituto de Salud Carlos III 10.13039/501100004587
                Funded by: Novartis Farmacéutica 10.13039/501100011772
                Categories
                Endocrinology
                Mini Review

                Endocrinology & Diabetes
                epithelial–menchymal transition,somatostatin analogs,pituitary,e-cadherin,somatotroph adenoma,growth hormone,pitnets,endocrine tumors

                Comments

                Comment on this article